IGMS

1.29

7.19% -0.10

Handel nachbörslich: 1.31 0.02 +1.55%

Igm Biosciences Inc (IGMS)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$1.39

Offen:

$1.35

24-Stunden-Volumen:

227.88K

Relative Volume:

0.51

Marktkapitalisierung:

$77.11M

Einnahmen:

$2.91M

Nettoeinkommen (Verlust:

$-220.40M

KGV:

-0.3544

EPS:

-3.64

Netto-Cashflow:

$-176.15M

1W Leistung:

-7.86%

1M Leistung:

-5.84%

6M Leistung:

-89.51%

1J Leistung:

-87.04%

1-Tages-Spanne:

$1.25

$1.43

1-Wochen-Bereich:

$1.25

$1.43

52-Wochen-Spanne:

$1.25

$22.50

Igm Biosciences Inc Stock (IGMS) Company Profile

Firmenname

Igm Biosciences Inc

Sektor

Healthcare (1169)

Branche

Biotechnology (679)

Telefon

650-965-7873

Adresse

325 E MIDDLEFIELD ROAD, MOUNTAIN VIEW

Mitarbeiter

149

Twitter

Nächster Verdiensttermin

2024-11-11

Neueste SEC-Einreichungen

IGMS's Discussions on Twitter

Vergleichen Sie IGMS mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
IGMS Igm Biosciences Inc	1.29	77.11M	2.91M	-220.40M	-176.15M	-3.64
VRTX Vertex Pharmaceuticals Inc	502.92	129.14B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	680.61	74.41B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	581.21	35.31B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	241.75	31.30B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	254.57	27.35B	3.32B	-860.46M	-1.04B	-8.32

Igm Biosciences Inc Stock (IGMS) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-01-10	Herabstufung	BMO Capital Markets	Outperform → Market Perform
2025-01-10	Herabstufung	Guggenheim	Buy → Neutral
2025-01-10	Herabstufung	Morgan Stanley	Equal-Weight → Underweight
2025-01-10	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2025-01-10	Herabstufung	Stifel	Buy → Hold
2024-12-06	Eingeleitet	BMO Capital Markets	Outperform
2024-10-01	Herabstufung	JP Morgan	Neutral → Underweight
2024-10-01	Herabstufung	Truist	Buy → Hold
2024-02-09	Hochstufung	RBC Capital Mkts	Sector Perform → Outperform
2023-12-15	Herabstufung	BofA Securities	Buy → Neutral
2023-12-07	Herabstufung	H.C. Wainwright	Buy → Neutral
2022-11-09	Fortgesetzt	Jefferies	Buy
2022-10-17	Eingeleitet	JP Morgan	Neutral
2022-08-29	Eingeleitet	BofA Securities	Buy
2021-12-13	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2021-11-05	Hochstufung	Wedbush	Neutral → Outperform
2021-08-26	Eingeleitet	Morgan Stanley	Overweight
2021-01-29	Eingeleitet	RBC Capital Mkts	Outperform
2021-01-19	Bestätigt	H.C. Wainwright	Buy
2020-12-22	Herabstufung	Wedbush	Outperform → Neutral
2020-07-17	Eingeleitet	Robert W. Baird	Outperform
2020-07-01	Eingeleitet	H.C. Wainwright	Buy
2020-05-28	Eingeleitet	SunTrust	Buy
2020-04-22	Eingeleitet	Wedbush	Outperform
2019-10-14	Eingeleitet	Guggenheim	Buy
2019-10-14	Eingeleitet	Jefferies	Buy
2019-10-14	Eingeleitet	Piper Jaffray	Overweight
2019-10-14	Eingeleitet	Stifel	Buy

Alle ansehen

Igm Biosciences Inc Aktie (IGMS) Neueste Nachrichten

Mar 08, 2025

IGM Biosciences Faces Uncertainty Amid Cash Preservation and Restructuring Efforts - TipRanks

Mar 08, 2025

Mar 07, 2025

IGM Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 07, 2025

Mar 05, 2025

Contrasting IGM Biosciences (NASDAQ:IGMS) and Gyre Therapeutics (NASDAQ:GYRE) - Defense World

Mar 05, 2025

Mar 03, 2025

IGM Biosciences stock plunges to 52-week low of $1.25 - Investing.com India

Mar 03, 2025

IGM Biosciences stock plunges to 52-week low of $1.25 By Investing.com - Investing.com South Africa

Mar 03, 2025

IGM Biosciences Inc expected to post a loss of 74 cents a shareEarnings Preview - TradingView

Mar 03, 2025

Mar 02, 2025

IGM Biosciences (IGMS) Projected to Post Quarterly Earnings on Thursday - MarketBeat

Mar 02, 2025

Mar 01, 2025